Antibe Therapeutics Completes Final Tranche of IPO, Bringing Total Raise to the Maximum Offering of $3,000,000

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE
UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A
VIOLATION OF U.S. SECURITIES LAWS


Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSX VENTURE:ATE) is
pleased to announce that on August 22, 2013 it completed its third and final
closing (the "Final Closing") under its initial public offering prospectus (the
"Prospectus"), raising gross proceeds of $269,799.75 and issuing 490,545 common
shares at a price of $0.55 per common share (the "Offering Price"). As
previously announced: (i) on June 18, 2013 Antibe completed its first closing
under the Prospectus raising gross proceeds of $2,127,400 and completed a
contemporaneous private placement raising $155,100; and (ii) on August 14, 2013,
and completed its second closing under the Prospectus, raising gross proceeds of
$602,800. With the Final Closing Antibe has achieved the maximum offering of
$3,000,000 under the Prospectus and accordingly distribution under the
Prospectus has ceased.


Burgeonvest Bick Securities Limited ("BBSL") acted as the lead agent and sole
bookrunner for a syndicate of agents, which included Euro Pacific Canada Inc.
(together with BBSL, the "Agents"). The Agents appointed a soliciting dealer
group of other registered dealers, including Bloom Burton and Co. Inc. Pursuant
to the Final Closing, the Agents received a commission of $26,979.98 and an
aggregate of 49,054 options (each, an "Agent's Option"), with each Agent's
Option entitling the holder to purchase one common share, at the Offering Price,
for a period of 24 months from the Final Closing. 


The Offering is made only by prospectus. The Prospectus contains important
detailed information about the securities being offered. Copies of the final
Prospectus can be obtained from Burgeonvest Bick Securities Limited, attention:
Ms. Vilma Jones, Managing Director, Head of Capital Markets, Syndication,
telephone (647) 347-4488. Investors should read the Prospectus before making an
investment decision.


An electronic copy of the final Prospectus filed in connection with the Offering
is available on SEDAR at www.sedar.com. 


About Antibe Therapeutics Inc.

Antibe Therapeutics Inc. originates, develops and out-licenses patent-protected
new pharmaceuticals that are improved versions of existing drugs. These
improvements are based on Nobel Prize-winning medical research highlighting the
crucial role of gaseous mediators, which are chemical substances produced in the
human body to regulate a range of fundamental cellular processes. The
Corporation's drug design methodologies involve chemically linking an existing
off-patent drug ("base drug") to an Antibe-patented, hydrogen sulfide-releasing
molecule. For medical conditions characterized by inflammation, pain or vascular
dysfunction, the Corporation's methodologies can efficiently produce improved
versions of a number of existing drugs. Notably, Antibe's products are
themselves fully patent-protectable and benefit from the predictable toxicity
and effectiveness profiles of the base drug.


United States Advisory

The securities referred to herein have not been and will not be registered under
the United States Securities Act of 1933, as amended (the "U.S. Securities
Act"), and may not be offered or sold in the United States unless the securities
are registered under the U.S. Securities Act, or an exemption from the
registration requirements of the U.S. Securities Act is available. This press
release shall not constitute an offer to sell or the solicitation of an offer to
buy any securities, nor shall there be any sale of securities in any state in
the United States in which such offer, solicitation or sale would be unlawful.


Forward-Looking Information

This press release contains forward-looking information that involves
substantial known and unknown risks and uncertainties, most of which are beyond
the control of Antibe, including, without limitation, those listed under the
headings "General Matters - Forward-Looking Statements" and "Risk Factors" in
Antibe's final prospectus. Forward-looking information in this press release
includes, but is not limited to, information concerning the prospectus offering
(including the terms of the Agent's Option). Should one or more of these risks
or uncertainties materialize, or should assumptions underlying the
forward-looking information prove incorrect, actual results, performance or
achievements could vary materially from those expressed or implied by the
forward-looking information. Accordingly, readers should not place undue
reliance on these forward-looking statements. These forward-looking statements
are made as of the date of this release and, other than as required by
applicable securities laws, Antibe does not assume any obligation to update or
revise them to reflect new events or circumstances.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
(416) 473 4095
dan.legault@antibethera.com
Antibe Therapeutics (TSXV:ATE)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024